An update from BeiGene Ltd ( (HK:6160) ) is now available.
BeiGene Ltd has announced the completion of a share purchase under its Fourth Amended and Restated 2018 Employee Share Purchase Plan (ESPP). During the offering period from September 3, 2024, to February 28, 2025, a total of 73,492 American Depositary Shares (ADSs) were purchased by 3,356 employees, representing approximately 0.068% of the total issued shares. The shares were offered at a 15% discount to market price, with no performance targets or clawback mechanisms attached. This initiative aligns with the company’s practice of offering competitive market benefits and supports employee investment in the company’s growth.
More about BeiGene Ltd
BeiGene Ltd is a biotechnology company focused on developing innovative molecularly targeted and immuno-oncology drug candidates for the treatment of cancer. The company operates in the pharmaceutical industry and is committed to improving treatment outcomes and access for patients globally.
YTD Price Performance: 34.16%
Average Trading Volume: 3,131,293
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: HK$216.5B
For detailed information about 6160 stock, go to TipRanks’ Stock Analysis page.